List of Contributors |
|
xiii | |
Preface and Acknowledgments |
|
xvii | |
I Cellular And Molecular Morphogenesis Of The Nervous System |
|
|
1 Brain Morphogenesis and Developmental Neurotoxicology |
|
|
|
|
|
|
3 | (1) |
|
II Man Proposed Computational Models be Integrated Over Three Levels |
|
|
4 | (1) |
|
III Morphogenetic Features Emerge From Interactions Across Multiple Levels of Biological Organization |
|
|
4 | (3) |
|
IV Whole Brain Assessment of Larval Zebrafish Reveals Patterns of Connectivity |
|
|
7 | (2) |
|
V Conclusions: Morphology Informs Predictive Models of Developmental Neurotoxicity |
|
|
9 | (1) |
|
|
10 | (7) |
|
2 Neural Cell Adhesion Molecules in Normal and Abnormal Neural Development |
|
|
|
|
|
|
|
|
|
|
|
|
17 | (1) |
|
II The Expression Levels of NCAM and PSA-NCAM During the Development |
|
|
18 | (1) |
|
III Regulating PSA-NCAM Expression and Cell Migration |
|
|
19 | (1) |
|
IV Requirement of PSA-NCAM for Activity-Induced Synaptic Plasticity |
|
|
19 | (2) |
|
|
21 | (2) |
|
3 Neurite Development and Neurotoxicity |
|
|
|
|
|
|
|
|
23 | (6) |
|
|
29 | (1) |
|
|
29 | (4) |
|
4 Myelin: Structure, Function, Pathology, and Targeted Therapeutics |
|
|
|
|
|
|
33 | (1) |
|
II Myelin Architecture and Assembly: Old and New Perspectives |
|
|
34 | (2) |
|
III Neuron-Glia Communication and its Regulation |
|
|
36 | (1) |
|
IV Myelinating Glial Cell Lineages in Peripheral and Central Nervous Systems |
|
|
37 | (2) |
|
V Chemical Composition of Vertebrate Myelin |
|
|
39 | (1) |
|
VI Dysmyelination: Myelin Mutant Models for Dysmyelination |
|
|
39 | (2) |
|
VII Demyelination: Effect of Various Factors on Developmental Myelination |
|
|
41 | (5) |
|
VIII Remyelination and CNS Disorders: Myelin to Axonal Regeneration |
|
|
46 | (1) |
|
IX Newer Treatment Strategies for Myelin Disorders |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
49 | (6) |
II Developmental Neurobiology/Toxicology |
|
|
|
|
|
|
|
55 | (1) |
|
II Expression Pattern and Regulation |
|
|
55 | (1) |
|
III Neurotrophin Receptors |
|
|
56 | (1) |
|
IV Neurotrophic Factors in Cell Survival and Cell Death |
|
|
57 | (1) |
|
V Neurotrophins and Synaptic Plasticity |
|
|
58 | (1) |
|
VI Neurotrophins and Behavior |
|
|
59 | (1) |
|
VII Other Neurotrophic Factors |
|
|
60 | (1) |
|
VIII Clinical Correlates to Neurodegenerative Disorders |
|
|
60 | (1) |
|
IX Clinical Correlates to Psychiatric Disorders |
|
|
61 | (1) |
|
|
62 | (1) |
|
XI Neurotrophins as Therapeutic Agents |
|
|
62 | (1) |
|
|
63 | (2) |
|
6 Serotonin Signaling as a Target for Craniofacial Embryotoxicity |
|
|
|
|
|
I Introduction-Serotonin and Embryonic Development |
|
|
65 | (1) |
|
II Serotonin Signal Transduction |
|
|
66 | (1) |
|
III Role of Serotonin in Development |
|
|
67 | (5) |
|
|
72 | (1) |
|
|
72 | (3) |
|
7 Neurotoxic and Neurotrophic Effects of GABAergic Agents on the Developing Brain |
|
|
|
|
|
75 | (1) |
|
II The GABAergic System During Development |
|
|
76 | (1) |
|
III GABAergic Agents and Consequences of Perturbations of GABAergic System Development |
|
|
76 | (1) |
|
IV Animal Models of GABAergic System Perturbation |
|
|
77 | (1) |
|
V In Vitro and Cell-Based Models of GABAergic System Perturbation During Neurodevelopment |
|
|
78 | (1) |
|
VI Bioinformatic and Computational Approaches |
|
|
78 | (1) |
|
VII Protecting the Developing GABAergic System: Prospects for the Future |
|
|
79 | (2) |
|
|
81 | (4) |
|
8 Neural Stem Cell Biology and Application to Developmental Neurotoxicity Assessment |
|
|
|
|
|
I Neural Stem Cells in the Developing Brain |
|
|
85 | (1) |
|
II Neural Stem Cells in the Adult Brain |
|
|
86 | (1) |
|
III NSCs-Derived From Embryonic Stem Cells and Induced Pluripotent Stem Cells |
|
|
87 | (1) |
|
IV Application of NSCs to Developmental Neurotoxicity Assessments |
|
|
87 | (1) |
|
|
88 | (1) |
|
|
89 | (2) |
|
9 Apoptosis as a Mechanism of Developmental Neurotoxicity |
|
|
|
|
|
|
|
91 | (1) |
|
II Molecular Mechanisms of Apoptosis in the Developing Nervous System |
|
|
92 | (3) |
|
III Physiological Roles of Apoptosis in Neurodevelopment |
|
|
95 | (1) |
|
IV Chemical-Induced Apoptosis |
|
|
96 | (10) |
|
|
106 | (1) |
|
|
106 | (7) |
|
10 Periods of Susceptibility: Interspecies Comparison of Developmental Milestones During Ontogenesis of the Central Nervous System |
|
|
|
|
|
|
113 | (1) |
|
II Overview of Central Nervous System Development |
|
|
114 | (6) |
|
III Developmental Milestones |
|
|
120 | (4) |
|
|
124 | (1) |
|
|
124 | (3) |
|
11 Modeling the Neurovascular Unit In Vitro and In Silico |
|
|
|
|
|
|
|
127 | (1) |
|
II Animal Models of BBB Development and Function |
|
|
128 | (1) |
|
|
128 | (2) |
|
IV Static Three-Dimensional (3D) Models |
|
|
130 | (1) |
|
V Organotypic Culture Models (OCMs) and Microphysiological Systems(MPS) |
|
|
131 | (2) |
|
VI Implementing In Vitro BBB Models for DNT |
|
|
133 | (4) |
|
VII In Silico Models: BBB Permeability |
|
|
137 | (1) |
|
VIII In Silico Models: Virtual NVU |
|
|
138 | (1) |
|
IX Summary and Conclusions |
|
|
138 | (1) |
|
|
139 | (4) |
|
12 Zebrafish as a Model for Developmental Biology and Toxicology |
|
|
|
|
|
|
143 | (1) |
|
|
144 | (2) |
|
III Developmental Toxicology |
|
|
146 | (1) |
|
IV Concordance With Mammalian Models |
|
|
147 | (1) |
|
|
148 | (1) |
|
|
148 | (5) |
|
13 Using Caenorhabditis Elegans to Study Neurotoxicity |
|
|
|
|
|
|
153 | (1) |
|
II Studies of Specific Neurotoxins |
|
|
154 | (3) |
|
III Anesthetic-Induced Neurotoxicity |
|
|
157 | (1) |
|
|
158 | (1) |
|
|
158 | (5) |
III Synaptogenesis And Neurotransmission |
|
|
14 Human 3D In Vitro Models for Developmental Neurotoxicity |
|
|
|
|
|
I Developmental Neurotoxicity Represents a Societal Testing Need |
|
|
163 | (1) |
|
II The Current Testing Approach for DNT In Vivo and In Vitro does not Satisfy Our Needs |
|
|
164 | (1) |
|
III The Process of Developing In Vitro Strategies for DNT |
|
|
164 | (2) |
|
IV The Development of a Reproducible BMPS for Modeling Neurodevelopment and Testing its Perturbation |
|
|
166 | (3) |
|
V Ongoing Developments of the Mini-Brain |
|
|
169 | (1) |
|
|
170 | (1) |
|
|
171 | (2) |
|
15 Ontogeny of Monoamine Neurotransmitters |
|
|
|
|
|
|
|
173 | (1) |
|
II Innervation of Terminal Fields |
|
|
174 | (1) |
|
III Neurochemical Synaptogenesis |
|
|
175 | (5) |
|
|
180 | (3) |
|
16 Developmental Toxicity Within the Central Cholinergic Nervous System |
|
|
|
|
|
|
|
|
183 | (1) |
|
II The Cholinergic System in CNS Development |
|
|
184 | (1) |
|
III Vulnerable Time Periods of Developmental Neurotoxicity |
|
|
185 | (1) |
|
IV Functional Effects of Developmental Exposure to Anticholinesterases |
|
|
185 | (1) |
|
V Cholinergic Mechanisms of Developmental Neurotoxicity |
|
|
186 | (4) |
|
VI Other Cholinergic Developmental Neurotoxicants |
|
|
190 | (2) |
|
|
192 | (1) |
|
|
193 | (6) |
|
17 Ontogeny of Second Messenger Systems |
|
|
|
|
|
|
|
|
|
|
|
199 | (1) |
|
II Second Messenger Systems: General and Ontogenic Aspects |
|
|
199 | (2) |
|
III Specific Roles of the Second Messenger System in Brain Development |
|
|
201 | (1) |
|
IV Developmental Neurotoxicants and Second Messenger Systems |
|
|
202 | (2) |
|
|
204 | (1) |
|
|
204 | (3) |
|
18 The NMDA Receptors: Physiology and Neurotoxicity in the Developing Brain |
|
|
|
|
|
|
207 | (1) |
|
II Molecular Structure of the NMDA Receptor |
|
|
208 | (1) |
|
III Functional Role &the NMDA Receptor |
|
|
209 | (1) |
|
IV Anatomical Distribution and Developmental Changes in NMDA Receptors in Brain |
|
|
210 | (1) |
|
V Role of the NMDA Receptor in Neurotoxicity During Brain Development |
|
|
210 | (2) |
|
|
212 | (5) |
IV Nutrient And Chemical Disposition |
|
|
19 Physiologically Based Pharmacokinetic (PBPK) Models |
|
|
|
|
|
|
|
217 | (1) |
|
II Selected PBPK Models for Developmental Neurotoxicology |
|
|
218 | (7) |
|
III Future Directions for Modeling CNS Active Materials |
|
|
225 | (1) |
|
|
225 | (4) |
|
20 Blood-Brain Barrier: Physiological and Functional Considerations |
|
|
|
|
|
|
|
|
|
|
229 | (1) |
|
II Development of the Blood-Brain Barrier |
|
|
230 | (2) |
|
III Disruption of the Blood-Brain Barrier |
|
|
232 | (2) |
|
|
234 | (1) |
|
|
234 | (3) |
|
21 Toxicological Mechanisms of Engineered Nanomaterials: Role of Material Properties in Inducing Different Biological Responses |
|
|
|
|
|
|
|
|
|
|
237 | (2) |
|
|
239 | (1) |
|
III The Role of Charge in Gold Nanotoxicity |
|
|
240 | (1) |
|
IV Toxicity of Amorphous Silica Nanoparticles |
|
|
240 | (1) |
|
V Unique Cellular Interactions of Silver Nanoparticles |
|
|
241 | (1) |
|
VI Chronic Toxicity of Nanoparticles in Enhanced Models |
|
|
242 | (1) |
|
VII Impact of Nanoparticles on Cellular Mitochondria |
|
|
243 | (2) |
|
VIII Understanding Molecular Mechanisms of Nanoparticle Toxicity Through Gene-Editing Technology |
|
|
245 | (1) |
|
|
246 | (5) |
|
22 Food and Nutrient Exposure Throughout the Life Span: How Does What We Eat Translate Into Exposure, Deficiencies, and Toxicities? |
|
|
|
|
|
251 | (1) |
|
|
252 | (1) |
|
III Bioavailability and Beyond |
|
|
253 | (1) |
|
IV Current Nutrient Standards |
|
|
254 | (1) |
|
V Global Causes of Deficiency |
|
|
254 | (1) |
|
VI Global Causes of Toxicity |
|
|
255 | (1) |
|
VII Effects of Deficiency and Excessive Amounts of Selected Nutrients |
|
|
255 | (4) |
|
VIII Approaches to Addressing Micronutrient Deficiencies |
|
|
259 | (1) |
|
IX Further Directions in Research About Lifelong Effects of Nutrition |
|
|
260 | (1) |
|
|
261 | (1) |
|
|
261 | (4) |
|
23 The Microbiome Gut-Brain Axis |
|
|
|
|
|
265 | (1) |
|
II What is the Human Microbiome? |
|
|
266 | (1) |
|
III What is the Gut-Brain Axis? |
|
|
267 | (1) |
|
IV Current Knowledge on How the Intestinal Microbiota Influences the Gut-Brain Axis |
|
|
268 | (1) |
|
V Intestinal Microbiota-Derived Neuroactive Metabolites |
|
|
269 | (1) |
|
VI Neurological Disorders |
|
|
269 | (1) |
|
VII Conclusions and Research Data Gaps |
|
|
270 | (1) |
|
Definitions for the Gut-Brain Axis |
|
|
271 | (1) |
|
|
271 | (4) |
|
24 Drug and Chemical Contaminants in Breast Milk: Effects on Neurodevelopment of the Nursing Infant |
|
|
|
|
|
|
|
275 | (1) |
|
II Effects of Breastfeeding on Infant Neurodevelopment |
|
|
276 | (1) |
|
III Exposure of Nursing Infants to Drugs in Breast Milk |
|
|
277 | (1) |
|
IV Effects of Maternal Exposure to Environmental Contaminants on the Nursing Infant |
|
|
278 | (2) |
|
V Drugs and Nonmedicinal Substances |
|
|
280 | (1) |
|
|
280 | (1) |
|
|
280 | (3) |
|
|
283 | (5) |
V Behavioral Assessment |
|
|
25 Behavioral Phenotyping in Developmental Neurotoxicology-Simple Approaches Using Unconditioned Behaviors in Rodents |
|
|
|
|
|
|
|
288 | (1) |
|
|
288 | (2) |
|
III Simple Unlearned Behaviors and Other Measures for Assessing Developmental Neurotoxicity |
|
|
290 | (7) |
|
IV Behavioral Test Batteries in Developmental Neurotoxicology |
|
|
297 | (4) |
|
|
301 | (1) |
|
|
302 | (8) |
|
26 Psychometric Tools to Study Cognition, Sensory Functioning, and Social Behavior in Infant and Adolescent Nonhuman Primates |
|
|
|
|
|
I Developmental Assessments for Young Macaque Infants (Birth to 3-4 Months of Age) |
|
|
310 | (2) |
|
II Assessing Cognition in Older Infants and Juveniles |
|
|
312 | (1) |
|
III Methodologies for Measuring Learning and Memory |
|
|
312 | (1) |
|
IV Tests of Cognition Suitable for Infant and Adolescent Monkeys |
|
|
313 | (1) |
|
V Raising the Bar on Difficulty: Measuring Complex Learning Abilities |
|
|
314 | (1) |
|
VI Tools to Measure Vision and Hearing |
|
|
315 | (1) |
|
VII Social Behavior in Play Groups and Mother-Infant Pairs |
|
|
316 | (1) |
|
|
317 | (1) |
|
|
317 | (4) |
|
27 Automated Assessment of Cognitive Function in Nonhuman Primates |
|
|
|
|
|
|
321 | (1) |
|
II Measuring Cognition Very Early in Life |
|
|
321 | (1) |
|
III Evaluation of Cognitive Abilities From Late Infancy Into Adulthood |
|
|
322 | (3) |
|
IV Toxicological Testing Using Operant Methods During Development |
|
|
325 | (1) |
|
|
326 | (3) |
|
28 Determining the Validity of Preclinical Behavioral Assessments for Extrapolation to a Clinical Setting |
|
|
|
|
|
|
329 | (2) |
|
|
331 | (1) |
|
|
332 | (1) |
|
|
332 | (1) |
|
|
333 | (1) |
|
|
333 | (1) |
|
|
334 | (1) |
|
|
335 | (3) |
|
29 Behavioral Outcome as a Primary Organizing Principle for Mechanistic Data in Developmental Neurotoxicity |
|
|
|
|
|
I Current Challenges in Risk Assessment |
|
|
338 | (1) |
|
II Organizing Principles for Mechanistic Data in Developmental Neurotoxicity are Needed Because the Brain is a "Complex Adaptive System" |
|
|
338 | (1) |
|
III Changes in Mechanistic Function During Neurodevelopment and Developmental Toxic Exposure May be Indistinguishable |
|
|
338 | (1) |
|
IV Behavior as an Organizing Principle for Mechanistic Data |
|
|
339 | (1) |
|
V Using a Single Behavioral Outcome at a Single Developmental Stage to Develop a Hierarchy of Mechanistic Effects: Rearing in Preadolescent Lead-Exposed Mice |
|
|
339 | (2) |
|
VI Which Mechanisms Have Been Associated With Mouse and Rat Rearing Behavior? |
|
|
341 | (1) |
|
VII Is There Mechanistic Evidence That Lead Exposure Disrupts Cholinergic Transmission? |
|
|
341 | (1) |
|
VIII How do We Understand Other Mechanistic Effects From Lead Exposure Relative to the Cholinergic System Disruption Indicated By Rearing Behavior? |
|
|
341 | (1) |
|
IX Does Evidence Suggest That Disruptions in the Cholinergic System Impact Glutamate/GABA Function? |
|
|
341 | (1) |
|
X What was Gained by Using Rearing Behavior at Preadolescence as a Starting Point for Organizing Extant Mechanistic Data? |
|
|
342 | (1) |
|
|
342 | (1) |
|
XII Using a Single Behavioral Outcome Measured at Multiple Developmental Stages to Understand the Salience of a Given Mechanism Across a Developmental Trajectory: Elevated Plus Maze (EPM) Performance as a Behavioral Measure of Anxiety |
|
|
342 | (1) |
|
XIII Bisphenol A as a Developmental Neurotoxicant |
|
|
342 | (1) |
|
XIV Anxiety as a Domain of Concern in BPA Risk Assessment |
|
|
343 | (1) |
|
XV EPM Anxiety and BPA Effects at Multiple Developmental Stages |
|
|
343 | (1) |
|
XVI What Brain Mechanisms are Relevant to EPM-Assessed Anxiety? |
|
|
343 | (1) |
|
XVII What Mechanism Pathways are Plausible Candidates for Developmental BPA Effects on EPM Anxiety? |
|
|
343 | (2) |
|
XVIII What is Gained by Using Behavior as an Organizing Principle? |
|
|
345 | (1) |
|
|
345 | (1) |
|
|
345 | (1) |
|
|
345 | (6) |
VI Clinical Assessment And Epidemiology |
|
|
30 Evaluation of the Human Newborn Infant |
|
|
|
|
|
|
|
351 | (1) |
|
|
352 | (1) |
|
III Neurobehavioral Evaluations |
|
|
353 | (3) |
|
|
356 | (1) |
|
V Neurophysiglogical Assessments |
|
|
357 | (1) |
|
|
358 | (1) |
|
|
359 | (1) |
|
|
359 | (4) |
|
31 Neuropsychological Assessment of Children in Studies of Developmental Neurotoxicity |
|
|
|
|
|
|
363 | (1) |
|
II Selecting the Age at Which to Conduct a Neuropsychological Assessment |
|
|
364 | (1) |
|
III Considerations in Designing an Assessment Battery |
|
|
364 | (3) |
|
|
367 | (2) |
|
|
369 | (2) |
|
32 Neurodevelopmental Assessment of the Older Infant and Child |
|
|
|
|
|
I Epidemiology of Pediatric Neurodevelopmental and Behavioral Disorders |
|
|
371 | (1) |
|
II Toolkit for Evaluation |
|
|
372 | (4) |
|
|
376 | (3) |
|
33 Longitudinal Studies of the Effects of Prenatal Cocaine Exposure on Development and Behavior |
|
|
|
|
|
I Methodological Issues in the Study of Prenatal Cocaine Exposure |
|
|
379 | (2) |
|
II A Longitudinal Study of Prenatal Cocaine Exposure: The Maternal Health Practices and Child Development Project |
|
|
381 | (2) |
|
III Results From the Maternal Health Practices and Child Development Project and Other Longitudinal Investigations of Prenatal Cocaine Exposure |
|
|
383 | (1) |
|
|
384 | (1) |
|
|
385 | (4) |
|
34 Assessment of Case Reports and Clinical Series |
|
|
|
|
|
389 | (1) |
|
II Recognition of Patterns of Anomalies |
|
|
389 | (1) |
|
III Syndromes of Cognitive or Behavioral Abnormalities |
|
|
390 | (4) |
|
IV Limitations of Pattern Recognition |
|
|
394 | (1) |
|
|
395 | (4) |
VII Specific Neurotoxic Syndromes |
|
|
35 Fetal Minamata Disease: A Human Episode of Congenital Methylmercury Poisoning |
|
|
|
|
|
|
|
|
399 | (1) |
|
|
399 | (1) |
|
III Neuropathology of Fetal Minamata Disease |
|
|
400 | (4) |
|
|
404 | (1) |
|
|
405 | (2) |
|
36 The Developmental Neurotoxicity of Cadmium |
|
|
|
|
|
|
407 | (1) |
|
II Prenatal and Postnatal Cadmium Exposure |
|
|
408 | (1) |
|
III Mechanisms of Developmental Neurotoxicity |
|
|
408 | (1) |
|
IV Neurobehavioral Outcomes in Animals |
|
|
409 | (1) |
|
V Neurodevelopmental Outcomes in Children and Adolescents |
|
|
410 | (1) |
|
|
411 | (1) |
|
|
411 | (3) |
|
37 Developmental Neurotoxicology of Lead: Neurobehavioral and Neurological Impacts |
|
|
|
|
I Lead Neurotoxicity in Children |
|
|
414 | (4) |
|
II Neurological Effects of Lead Neurotoxicity in Animals: Cognition and Plasticity |
|
|
418 | (5) |
|
|
423 | (4) |
|
38 Fetal Alcohol Spectrum Disorder |
|
|
|
|
|
|
|
427 | (1) |
|
II Epidemiology of Alcohol Consumption in Pregnancy |
|
|
428 | (1) |
|
III Alcohol Mechanism of Action |
|
|
428 | (2) |
|
|
430 | (1) |
|
V Epidemiology of FASD and Economic Burden |
|
|
430 | (1) |
|
|
430 | (2) |
|
|
432 | (1) |
|
VIII FASD and Mental Health |
|
|
433 | (1) |
|
IX FASD Challenges and Future Directions |
|
|
434 | (1) |
|
|
434 | (1) |
|
|
435 | (1) |
|
|
435 | (4) |
|
39 Developmental Neurotoxicity of Nicotine and Tobacco |
|
|
|
|
|
I Tobacco and Nicotine Exposure During Pregnancy |
|
|
439 | (1) |
|
II Epidemiological Studies Find Neurobehavioral Dysfunction Associated With Tobacco Exposure in Pregnancy |
|
|
440 | (1) |
|
III Animal Models Show That Nicotine Exposure During Development Causes Neurobehavioral Impairment |
|
|
441 | (2) |
|
IV Nicotine Disrupts Neuronal Development |
|
|
443 | (2) |
|
V Neurotoxicity of Other Compounds in Tobacco |
|
|
445 | (1) |
|
|
446 | (1) |
|
VII Other Nicotinic Compounds |
|
|
447 | (1) |
|
|
447 | (1) |
|
|
448 | (5) |
|
40 Developmental Neurobehavioral Neurotoxicity of Insecticides |
|
|
|
|
|
|
453 | (1) |
|
|
454 | (2) |
|
|
456 | (2) |
|
|
458 | (1) |
|
|
459 | (1) |
|
|
460 | (1) |
|
|
461 | (1) |
|
|
462 | (5) |
|
41 Developmental Exposure to Polychlorinated Biphenyls Induces Deficits in Inhibitory Control and May Enhance Substance Abuse Risk |
|
|
|
|
|
|
467 | (1) |
|
II Developmental Neurobehavioral Neurotoxicity of PCBs |
|
|
468 | (2) |
|
III Developmental PCB Exposure Impairs Dopamine Function |
|
|
470 | (1) |
|
IV Perinatal PCB Exposure Changes the Developing Brain, But Males May Be More Sensitive |
|
|
471 | (1) |
|
V Where Do We Go From Here? |
|
|
472 | (1) |
|
|
472 | (5) |
|
42 Developmental Neurotoxicity of General Anesthetics |
|
|
|
|
|
|
477 | (1) |
|
II Classes of Anesthetics and Mechanisms of Action |
|
|
477 | (1) |
|
III Nonclinical Studies of Anesthetic-Induced Neurotoxicity |
|
|
478 | (2) |
|
|
480 | (2) |
|
|
482 | (1) |
|
|
482 | (1) |
|
|
482 | (5) |
|
43 Maternal Drug Abuse and Adverse Effects on Neurobehavior of Offspring |
|
|
|
|
|
487 | (2) |
|
|
489 | (2) |
|
|
491 | (1) |
|
IV Cannabinoids/Marijuana |
|
|
492 | (2) |
|
|
494 | (1) |
|
|
494 | (1) |
|
VII Transgenerational and Paternal Exposures |
|
|
495 | (1) |
|
|
495 | (1) |
|
|
495 | (4) |
|
44 Developmental Neurotoxicology of Antiepileptic Drugs |
|
|
|
|
|
|
|
|
499 | (1) |
|
II Neurobehavioral Effects of Prenatal Exposure to Monotherapy Treatment |
|
|
500 | (5) |
|
III Putative Underlying Causes of Neuroteratogenic Effects |
|
|
505 | (1) |
|
|
506 | (1) |
|
|
507 | (4) |
VIII Risk Assessment |
|
|
45 Current Approaches to Risk Assessment for Developmental Neurotoxicity |
|
|
|
|
|
|
511 | (1) |
|
II Risk Assessment Paradigm and General Concepts |
|
|
512 | (1) |
|
III Conduct and Considerations in Developmental Neurotoxicity Risk Assessment |
|
|
513 | (9) |
|
IV Common Data Gaps for DNT Studies of Environmental Chemicals |
|
|
522 | (1) |
|
|
523 | (1) |
|
|
524 | (3) |
|
46 Animal/Human Concordance |
|
|
|
|
|
|
527 | (1) |
|
|
528 | (2) |
|
III Assessment of Neurobehavioral Development in Infants and Children |
|
|
530 | (1) |
|
|
530 | (4) |
|
|
534 | (1) |
|
VI Newer Models and Approaches |
|
|
535 | (1) |
|
|
536 | (3) |
|
47 Physiologically Based Pharmacokinetic Models in the Risk Assessment of Developmental Neurotoxicants |
|
|
|
|
|
539 | (1) |
|
II Construction and Evaluation of PBPK Models |
|
|
540 | (6) |
|
III Brain Dosimetry in PBPK Models |
|
|
546 | (2) |
|
IV PBPK Modeling of Developmental Neurotoxicants |
|
|
548 | (2) |
|
V Application of PBPK Models in the Risk Assessment of Developmental Neurotoxicants |
|
|
550 | (3) |
|
|
553 | (6) |
|
48 Application of Quantitative Dose-Response Data in Risk Assessment and the Incorporation of High-Throughput Data |
|
|
|
|
|
559 | (1) |
|
|
560 | (3) |
|
III Risk Assessment Fundamentals in the Federal Government |
|
|
563 | (2) |
|
|
565 | (2) |
|
V Data From High-Throughput Assays |
|
|
567 | (1) |
|
|
568 | (4) |
|
|
572 | (1) |
Index |
|
573 | |